In Move to Power Precision Oncology for Patients, COTA and Genomic Testing Cooperative Form New Data Partnership
The two companies are joining forces to integrate COTA’s deep clinical oncology real-world data with GTC’s comprehensive genomics testing data.
How Real-World Data Helps Explore Alternative Dosing for Colorectal, Pancreatic Cancer Therapy
Research from MedStar Georgetown Lombardi Comprehensive Cancer Center and COTA shows the potential of a more patient-friendly dosing regimen for Stage 4 CRC/PC or locally advanced PC.
This collaboration highlights how real-world data can contribute to clinical research and can help answer pressing questions about care already taking place in clinical practice.
Key Takeaways from ASH 2022: Real-World Data Gets Down to Business
The American Society of Hematology’s 2021 annual meeting showed that real-world data is no longer the new kid on the block – it’s an indispensable part of the toolkit for therapeutic development and clinical research. COTA is proud to be a part of the discussion, contributing research this year for chronic lymphocytic leukemia.
Are Pharma Companies Ready to Harness the Promises of Real-World Data?
Partnering with Impatient Health, we take a comprehensive look at the realities of real-world data and the challenges that pharma companies face in leveraging it to gain actionable insight, based on feedback from executives at well-known, major pharma companies.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
The Power of Collaboration: ASH Showcases COTA’s Real World Data and Research at Annual Meeting
COTA is honored to have contributed to three abstracts accepted for poster presentation at the American Society of Hematology’s 64th Annual Meeting, which cover a range of hematologic cancers. These studies focus on patient- and clinician-reported performance status in Multiple Myeloma, and real-world treatment patterns among patients with newly diagnosed Acute Myeloid Leukemia in the US.
COTA and Google Partner to Use Natural Language Processing to Harness Unstructured Data
We are excited to announce our partnership with Google Cloud to use their Natural Language Processing (NLP) technology to help us better understand the unstructured data in cancer patients’ medical records.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
The COTA Team Expands as Demand for RWD Surges
2022 has been a time of extraordinary growth at COTA including many new faces that we are proud to welcome to our team.
Noel Alaka Joins COTA’s Life Science Team to Accelerate Adoption of Oncology Real-World Data
After working at one of the world’s leading global clinical research organizations, Noel joins us to continue his work advocating for patients and helping to advance therapeutic and diagnostic options for all.
Making the Most of Real-World Data: Addressing Cancer Disparities Starts with All of Us
COTA President & CEO, Miruna Sasu, gave a keynote speech at the DIA 2022 Global Annual Meeting on healthcare disparities. She shared her personal story of how her family benefited from clinical trials and how she is now working to open those opportunities for others.
Meet Our Interns!
We are so excited to welcome our 8 new interns for our 2022 internship program – learn a little bit more about each the newest additions to COTA.
